Compare AUR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUR | PRAX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 9.6B |
| IPO Year | N/A | 2020 |
| Metric | AUR | PRAX |
|---|---|---|
| Price | $4.36 | $308.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $10.34 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 15.8M | 331.9K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $408.03 | N/A |
| Revenue Next Year | $1,167.57 | $6,395.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.60 | $26.70 |
| 52 Week High | $8.25 | $354.87 |
| Indicator | AUR | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 44.09 | 43.37 |
| Support Level | $4.05 | $290.36 |
| Resistance Level | $4.96 | $322.32 |
| Average True Range (ATR) | 0.27 | 19.36 |
| MACD | -0.04 | -4.96 |
| Stochastic Oscillator | 20.13 | 26.43 |
Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, a scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.